Christian Cadeddu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3747242/publications.pdf

Version: 2024-02-01

92 papers	8,874 citations	201575 27 h-index	54882 84 g-index
98 all docs	98 docs citations	98 times ranked	15293 citing authors

#	Article	IF	Citations
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
2	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	2.9	533
3	Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers. Oncologist, 2007, 12, 1124-1133.	1.9	127
4	Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal, 2010, 160, 487.e1-487.e7.	1.2	127
5	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 2018, 9, 167.	1.3	118
6	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxidants and Redox Signaling, 2019, 30, 2110-2153.	2.5	96
7	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	1.9	94
8	Gender determinants of cardiovascular risk factors and diseases. Journal of Cardiovascular Medicine, 2010, 11, 207-220.	0.6	82
9	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. Journal of Cardiovascular Medicine, 2016, 17, e12-e18.	0.6	78
10	Long-term, up to 18Âmonths, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. SpringerPlus, 2013, 2, 198.	1.2	55
11	Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Experimental and Therapeutic Medicine, 2011, 2, 1003-1009.	0.8	51
12	Women-specific predictors of cardiovascular disease risk - new paradigms. International Journal of Cardiology, 2019, 286, 190-197.	0.8	49
13	Metabolomic approach to profile functional and metabolic changes in heart failure. Journal of Translational Medicine, 2015, 13, 297.	1.8	47
14	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e84-e92.	0.6	47
15	Metabolomics, a promising approach to translational research in cardiology. IJC Metabolic & Endocrine, 2015, 9, 31-38.	0.5	46
16	The different role of sex hormones on female cardiovascular physiology and function: not only oestrogens. European Journal of Clinical Investigation, 2015, 45, 634-645.	1.7	43
17	Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers. Oncologist, 2008, 13, 1296-1305.	1.9	40
18	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Failure Reviews, 2015, 20, 621-631.	1.7	40

#	Article	IF	Citations
19	Current views on anthracycline cardiotoxicity. Heart Failure Reviews, 2016, 21, 621-634.	1.7	39
20	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Failure Reviews, 2019, 24, 915-925.	1.7	39
21	Arterial hypertension in the female world. Journal of Cardiovascular Medicine, 2016, 17, 229-236.	0.6	38
22	Metabolomics. Journal of Cardiovascular Medicine, 2011, 12, 800-805.	0.6	37
23	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e93-e104.	0.6	37
24	Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. American Heart Journal, 2002, 144, 796-803.	1.2	37
25	Cardioprotection by gene therapy. International Journal of Cardiology, 2015, 191, 203-210.	0.8	34
26	Effects of an Aquaticâ€Based Exercise Program to Improve Cardiometabolic Profile, Quality of Life, and Physical Activity Levels in Men With Type 2 Diabetes Mellitus. PM and R, 2015, 7, 141-148.	0.9	33
27	Non-invasive coronary flow reserve is correlated with microvascular integrity and myocardial viability after primary angioplasty in acute myocardial infarction. Heart, 2006, 92, 1113-1118.	1.2	30
28	Distinctive metabolomic fingerprint in scleroderma patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 241, 401-406.	0.8	28
29	Potential cardiac risk of immuneâ€checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. Medicinal Research Reviews, 2018, 38, 1447-1468.	5.0	27
30	Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. Journal of Cardiovascular Medicine, 2018, 19, 315-323.	0.6	27
31	Early impairment of contractility reserve in patients with insulin resistance in comparison with healthy subjects. Cardiovascular Diabetology, 2013, 12, 66.	2.7	24
32	Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients. Cardiovascular Diabetology, 2014, 13, 93.	2.7	24
33	Significant QT interval prolongation and long QT in young adult ex-preterm newborns with extremely low birth weight. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 1115-1118.	0.7	23
34	Altered Transmural Contractility in Postmenopausal Women Affected by Cardiac Syndrome X. Journal of the American Society of Echocardiography, 2014, 27, 208-214.	1.2	23
35	Preventing antiblastic drug-related cardiomyopathy. Journal of Cardiovascular Medicine, 2016, 17, e64-e75.	0.6	23
36	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). Antioxidants, 2020, 9, 641.	2.2	23

#	Article	IF	Citations
37	Gender differences in cardiology: is it time for new guidelines?. Journal of Cardiovascular Medicine, 2018, 19, 685-688.	0.6	22
38	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e35-e44.	0.6	20
39	Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac followâ€up. British Journal of Haematology, 2018, 180, 879-888.	1.2	20
40	Role of biomarkers in monitoring antiblastic cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e27-e34.	0.6	18
41	Blood metabolomic fingerprint is distinct in healthy coronary and in stenosing or microvascular ischemic heart disease. Journal of Translational Medicine, 2017, 15, 112.	1.8	18
42	Cardiovascular modulation during vagus nerve stimulation therapy in patients with refractory epilepsy. Epilepsy Research, 2010, 92, 145-152.	0.8	17
43	Heart rate variability shows different cardiovascular modulation in Parkinsonâ€™s disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype. Journal of Neural Transmission, 2015, 122, 1441-1446.	1.4	17
44	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e45-e54.	0.6	17
45	Echocardiographic accidental finding of asymptomatic cardiac and pulmonary embolism caused by cement leakage after percutaneous vertebroplasty. European Heart Journal Cardiovascular Imaging, 2009, 10, 590-592.	0.5	16
46	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. Journal of Clinical Medicine, 2020, 9, 820.	1.0	16
47	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). European Heart Journal Cardiovascular Imaging, 2021, 22, 406-415.	0.5	16
48	Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance. International Journal of Cardiovascular Imaging, 2015, 31, 529-536.	0.7	15
49	Evaluation of left atrial appendage function and thrombi in patients with atrial fibrillation: from transthoracic to real time 3D transesophageal echocardiography. International Journal of Cardiovascular Imaging, 2017, 33, 491-498.	0.7	15
50	Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection. International Journal of Molecular Sciences, 2019, 20, 4928.	1.8	13
51	Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity. Antioxidants and Redox Signaling, 2021, 34, 572-588.	2.5	12
52	Cardiopulmonary and endothelial effects of metformin treatment in an insulin resistant population. International Journal of Cardiology, 2012, 158, 302-304.	0.8	11
53	Non-invasive estimation of stroke volume during exercise from oxygen in heart failure patients. European Journal of Preventive Cardiology, 2021, 28, 280-286.	0.8	11
54	Cardiovascular Risk Perception and Knowledge among Italian Women: Lessons from IGENDA Protocol. Journal of Clinical Medicine, 2022, 11, 1695.	1.0	11

#	Article	IF	Citations
55	Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy. International Journal of Cardiovascular Imaging, 2017, 33, 197-207.	0.7	10
56	Metabolomic fingerprint of coronary blood in STEMI patients depends on the ischemic time and inflammatory state. Scientific Reports, 2019, 9, 312.	1.6	10
57	Effects of Metformin and Exercise Training, Alone or in Combination, on Cardiac Function in Individuals with Insulin Resistance. Cardiology and Therapy, 2016, 5, 63-73.	1.1	9
58	Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. Journal of Clinical Medicine, 2020, 9, 1180.	1.0	9
59	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Ã— 2 phenotypic CAPIRE study. International Journal of Cardiology, 2021, 336, 14-21.	0.8	9
60	High prevalence of interatrial septal aneurysm in young adults who were born preterm. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 1123-1128.	0.7	8
61	Metabolomic Approach to Redox and Nitrosative Reactions in Cardiovascular Diseases. Frontiers in Physiology, 2018, 9, 672.	1.3	8
62	Effects of a mini-trampoline rebounding exercise program on functional parameters, body composition and quality of life in overweight women. Journal of Sports Medicine and Physical Fitness, 2018, 58, 287-294.	0.4	8
63	Non-invasive coronary imaging in patients with COVID-19: A narrative review. European Journal of Radiology, 2022, 149, 110188.	1.2	8
64	Clinical applications of contrast echocardiography. American Heart Journal, 2001, 141, S36-S44.	1.2	6
65	Relationship between high values of HOMA-IR and cardiovascular response to metformin. International Journal of Cardiology, 2013, 167, 282.	0.8	6
66	Early ischemia identification employing 2D speckle tracking selective layers analysis during dobutamine stress echocardiography. Echocardiography, 2019, 36, 2202-2208.	0.3	6
67	Sexâ€related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. Journal of Cellular and Molecular Medicine, 2022, , .	1.6	6
68	Contrast-Enhanced Harmonic Color Doppler for Left Ventricular Opacification: Improved Endocardial Border Definition Compared to Tissue Harmonic Imaging and Optimization of Methodology in Patients with Suboptimal Echocardiograms. Echocardiography, 2001, 18, 639-649.	0.3	5
69	Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells. Current Drug Targets, 2017, 18, 719-723.	1.0	5
70	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. Metabolites, 2022, 12, 123.	1.3	5
71	Inverted Takotsubo Cardiomyopathy Induced by Dobutamine Stress Echocardiography with Atypical Presentation. Case Reports in Cardiology, 2011, 2011, 1-3.	0.1	4
72	Early right ventricular dysfunction in highly selected (totally free from cardiovascular risk factors) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 echocardiography. Journal of Cardiovascular Echography, 2018, 28, 228.	0.1	3

#	Article	IF	Citations
73	The Echocardiographic Parameters of Systolic Function Are Associated with Specific Metabolomic Fingerprints in Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy. Metabolites, 2021, 11, 787.	1.3	3
74	Multimodality imaging diagnosis of multiple ventricular thrombosis and massive stroke after gemcitabine and cisplatin chemotherapy for Urothelial Cancer. Journal of Cardiovascular Echography, 2019, 29, 71.	0.1	2
75	Vascular damage â€“ Coronary artery disease. Journal of Cardiovascular Echography, 2020, 30, 11.	0.1	2
76	Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. Blood, 2019, 134, 4144-4144.	0.6	2
77	1261 POSTER Long-term Protective Effects of the Angiotensin Receptor Blocker Telmisartan on Epirubicin-induced Inflammation, Oxidative Stress and Myocardial Dysfunction. European Journal of Cancer, 2011, 47, S163.	1.3	1
78	Subclinical contractility impairment in HIV-infected patients: Dependence on the class of antiretroviral drugs. International Journal of Cardiology, 2013, 168, 1538-1539.	0.8	1
79	Left atrial myxoma with an extremely mobile thread-like offshoot. Journal of Echocardiography, 2015, 13, 116-117.	0.4	1
80	The need of a gender-corrected evidence based medicine. International Journal of Cardiology, 2018, 255, 156-157.	0.8	1
81	Diastolic Function in Systemic Sclerosis Patients. Journal of the American College of Cardiology, 2018, 72, 1814-1816.	1.2	1
82	Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and myocardial dysfunction.. Journal of Clinical Oncology, 2012, 30, 9006-9006.	0.8	1
83	Early Ventricular Dysfunction in Type II Diabetes: Role of Metabolic Unbalance. Journal of Diabetes & Metabolism, 2013, 01, .	0.2	1
84	Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by â€œspeckle trackingâ€•echocardiography (STE).. Journal of Clinical Oncology, 2013, 31, 603-603.	0.8	1
85	3023 Cardioprotective effect of telmisartan in cancer patients treated with epirubicin. European Journal of Cancer, Supplement, 2009, 7, 182.	2.2	0
86	Trastuzumab-Induced Early Cardiac Dysfunction Assessed by Speckle Tracking Echocardiography: Correlation with Chronic Inflammation and Oxidative Stress Markers. Annals of Oncology, 2012, 23, ix164.	0.6	0
87	Negative effects of trastuzumab adjuvant chemotherapy on cardiac mechanics. role of specific myocardial layers. European Heart Journal, 2013, 34, 2716-2716.	1.0	0
88	Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers. Journal of Clinical Oncology, 2008, 26, 20517-20517.	0.8	0
89	Cardioprotective effect of telmisartan in cancer patients treated with telmisartan.. Journal of Clinical Oncology, 2010, 28, 9153-9153.	0.8	0
90	Taxane associated with trastuzumab-induced early ventricular impairment: Correlation with biologic markers of chronic inflammation and oxidative stress.. Journal of Clinical Oncology, 2014, 32, e11566-e11566.	0.8	0

#	Article	IF	Citations
91	Effects Of A Home-based Rehabilitation Program Supervised By A Telemedicine System In Patients With Chronic Heart Failure (NYHA II/III). Medicine and Science in Sports and Exercise, 2014, 46, 438.	0.2	0
92	To be or not to be resilient in familial hypercholesterolaemia: implications for the management. European Journal of Preventive Cardiology, 2021, , .	0.8	0